Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation

Results of a multi-institutional clinical trial that included a UC San Francisco researcher indicate that use of an experimental drug known as TPO increases the number of people who are medically eligible for autologous stem cell transplantation, a procedure used to replenish the blood cells of cancer patients following high dose chemotherapy.

The trial demonstrated that the recombinant, or genetically engineered, drug, called platelet growth factor thrombopoetin, is effective in stimulating stem cells --the body's primitive bone marrow cells and the ultimate source of all blood cells-- to migrate out of the bone marrow and into the bloodstream. There, they can be collected and stored for safekeeping while patients undergo chemotherapy, which kills both healthy and cancerous cells. The stem cells can then be transplanted back into the patients, providing a fresh supply of healthy blood cells and restoring bone marrow function.

Traditionally, another growth factor, G-CSF, has been relied upon to stimulate stem cell migration into the bloodstream. However, the drug often is unable to stimulate a sufficient number of cells to migrate into the blood. In these cases, patients are unable to receive the extremely intensive regimens of chemotherapy that they need.

The findings, which will be presented at the American Society of Hematology meeting in Miami on Monday, Dec. 7, indicate that TPO helps mobilize stem cells for collection when used in conjunction with G-CSF, according to the lead author of the study, Charles Linker, MD, a clinical professor of medicine and director of the UCSF-Stanford Health Care Adult Leukemia and Bone Marrow Transplant Program at UCSF.

The current phase II clinical trial, conducted in 134 patients, established that TPO, administered in conjunction with G-CSF, significantly boosts the odds of stem cells migrating into the bloodstream in sufficient numbers to stimulate re-growth of blood cells.

The majority of patient

Contact: Jennifer O'Brien
University of California - San Francisco

Page: 1 2

Related medicine news :

1. Clinical breast examination offers modest benefit to breast cancer screening program
2. Clinical trial of Etanercept for Wegeners disease shows no benefit
3. Clinical trial participants fare no better, no worse than other patients
4. Clinical trial shows drug may offer a new option to prevent rejection of transplanted kidneys
5. National Academies news: Clinical research involving children
6. Clinical research key in advance to prospective health care
7. Clinical trial of new TB vaccine begins
8. Clinical trial of Alzheimers disease drug shows clear reductions in AD development
9. Clinical factors useful to identify heart failure patients with high risk of death
10. Panel: Clinical use of embryonic stem cells jeopardized by Bushs policy on federal funding
11. $7 million grant continues Asthma Clinical Research Network efforts

Post Your Comments:

(Date:7/10/2020)... ... 10, 2020 , ... Worries and anxiety about COVID-19 and ... and social distancing makes it even more challenging. "For folks with a spinal ... PTSD amongst our adult population and children alike," states Greg Jamian, MSCIA Chairman. ...
(Date:7/10/2020)... Calif. (PRWEB) , ... July 10, 2020 , ... Traliant, ... today announced a new training course for managers on the Family and Medical Leave ... FMLA with paid sick and family leave provisions related to COVID-19. , ...
(Date:7/7/2020)... ... July 07, 2020 , ... The Germ-Fogger™ disinfecting ... to efficiently sanitize large surfaces is now available in Mexico and Latin America. ... in that region. , In this era of worldwide pandemic, the ability to ...
(Date:7/2/2020)... YORK (PRWEB) , ... July 02, 2020 , ... ... New York plastic and cosmetic surgeons, with medical offices located in Staten Island, Huntington ... will be relocating to a beautifully designed medical suite at The Parlor NYC at ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... terpenes, has officially released its new terpene infused product line including custom ... consumers to enjoy cannabis terpene profiles and flavors worldwide. , “We’ve made it ...
Breaking Medicine News(10 mins):
(Date:7/10/2020)... ... July 10, 2020 , ... Precision ADM, Inc. (“Precision ... provider today announced that their CANSWAB™ nasopharyngeal swabs are the first Canadian-made COVID-19 ... new 3D-printed swab design and has trademarked the name CANSWAB™ for distribution. The ...
(Date:7/10/2020)... ... July 10, 2020 , ... ... business and technology for the pharmaceutical industry throughout North America has launched ... highest quality pharmaceutical products. QC Corner will feature content from ...
(Date:7/7/2020)... , ... July 07, 2020 , ... SupplyPro announces a ... spread of COVID-19 is affecting every one of us. SupplyPro is dedicated to supporting ... to run a Contact Tracing Report - a powerful tool in the fight against ...
Breaking Medicine Technology:
Cached News: